Donald S Backos (D S Backos)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 8

Top Venues

Chemical research in toxicology

ChemMedChem

Journal of cellular biochemistry

Scientific reports

University of Colorado Denver School of Pharmacy

University of Colorado Denver (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Colorado Denver School of Pharmacy Feb 01 2016

United States

Assistant Research Professor :: Pharamceutical Sciences

Subunit Studios, Ltd Jul 07 2014

United States

Creative Director

University of Colorado Denver School of Pharmacy May 01 2014 - Jan 31 2016

United States

Research Instructor :: Pharmaceutical Sciences

University of Colorado Denver School of Pharmacy Jan 01 2013 - Apr 30 2014

United States

Research Associate :: Pharmaceutical Sciences

University of Colorado Denver School of Pharmacy Dec 01 2010 - Dec 31 2012

United States

Postdoctoral Fellow :: Pharmaceutical Sciences

University of Colorado Aug 25 2005 - Nov 30 2010

United States

Graduate Student :: Toxicology

University of Michigan Medical School Apr 02 2002 - Jul 31 2005

United States

Research Assistant II :: Pharmacology

NSF International May 04 2001 - Jan 31 2002

United States

Toxicology Intern :: Toxicology

Education History

University of Colorado Denver Aug 25 2005 - Nov 17 2010

United States

PHD :: Pharmaceutical Sciences

University of Michigan Sep 01 1995 - May 15 1999

United States

BSC

Publications

Lindsay W Brubaker, Donald S Backos, Vu T Nguyen, Philip Reigan, Tomomi M Yamamoto, Elizabeth R Woodruff, Ritsuko Iwanaga, Michael F Wempe, Vijay Kumar, Christianne Persenaire, Zachary L Watson, Benjamin G Bitler
Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert opinion on therapeutic targets (2023)
Alec G Trub, Gregory R Wagner, Kristin A Anderson, Scott B Crown, Guo-Fang Zhang, J Will Thompson, Olga R Ilkayeva, Robert D Stevens, Paul A Grimsrud, Rhushikesh A Kulkarni, Donald S Backos, Jordan L Meier, Matthew D Hirschey
Statin therapy inhibits fatty acid synthase via dynamic protein modifications. Nature communications 13 (1) (2022)
Guodong Pan, Mandar Deshpande, Haiyan Pang, Paul M Stemmer, Nicholas J Carruthers, Colin T Shearn, Donald S Backos, Suresh Selvaraj Palaniyandi
4-Hydroxy-2-nonenal attenuates 8-oxoguanine DNA glycosylase 1 activity. Journal of cellular biochemistry (2020)
I Cruz-Torres, Donald S Backos, P S Herson
Characterization and Optimization of the Novel Transient Receptor Potential Melastatin 2 Antagonist tatM2NX. Molecular pharmacology 97 (2) (2019)
Christopher J Matheson, Kimberly A Casalvieri, Donald S Backos, Philip Reigan
Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. ChemMedChem 13 (16) (2018)
Cecilia M Borghese, Melissa Herman, Lawrence D Snell, Keri J Lawrence, Hyun-Young Lee, Donald S Backos, Lauren A Vanderlinden, R Adron Harris, Marisa Roberto, Paula L Hoffman, Boris Tabakoff
Novel Molecule Exhibiting Selective Affinity for GABAA Receptor Subtypes. Scientific reports 7 (1) (2017)
Peter S Harris, Joe D Gomez, Donald S Backos, Kristofer S Fritz
Characterizing Sirtuin 3 Deacetylase Affinity for Aldehyde Dehydrogenase 2. Chemical research in toxicology 30 (3) (2017)
Fangfang Chen, Guankui Wang, James I Griffin, Barbara Brenneman, Nirmal K Banda, V Michael Holers, Donald S Backos, LinPing Wu, Seyed Moein Moghimi, Dmitri Simberg
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nature nanotechnology 12 (4) (2016)

Donald S Backos.css-eqlu8i{font-size:small;padding-left:4px;} (D S Backos)

Publication Activity (10 Years)

Top Topics

Top Venues

Donald S Backos (D S Backos)